[Myocardial protection during extracorporeal circulation. Preliminary results with different techniques].
Great advances in surgical techniques, perfusion technology and cardiac anesthesia have made heart surgery safer. However, the mayor advance over the past 15 years has been in the field of myocardial protection. Much remains to be done in this field and there is not complete agreement about the different methods of myocardial protection. At the Institute of Cardiac Surgery of Parma a research is developing to concern three different cardioprotective strategies, of which preliminary results are showing. Three groups of patients with the same clinical, surgical, anesthesiological features, who underwent cardiac surgery have been selected. In patients of group A intermittent cold hyperkalemic crystalloid cardioplegia has been used, in those of group B intermittent cold blood cardioplegia and in those of group C intermittent cold blood cardiolegia associated a warm glucose blood cardioplegic reperfusion before aortic unclamping. In all patients enzyme levels (CPK; CPK-MB; LHD; SGOT; SGPT) were measured 12, 24, 72, 120 hours postoperatively; data were collected, also, on spontaneous return to sinus rhythm, perioperative myocardial infarction and the need or not for inotropic agents. All data at first and then those of patients who underwent only coronary rivascularization (75% of patients) were statistically analyzed (one-way Fischer's test). It appears that the use of antegrade cold intermittent blood cardioplegia with reperfusion is more optimal for myocardial protection, how show lower levels of CPK-MB especially in the first postoperative period. In group C remains greater spontaneous resumption of normal sinus rhythm compare to group A and this suggests a best preservation of cellula-integrity and function with use of blood cardioplegia.
Spaggiari
I
I
Cattedra di Chirurgia del Cuore e Grossi Vasi, Università degli Studi di Parma.
Cavozza
C
C
Fesani
F
F
D'Amico
E
E
Menozzi
E
E
Sciaraffia
M
M
D006348:Cardiac Surgical Procedures; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D005112:Extracorporeal Circulation; D006321:Heart / Q000187:drug effects*; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*; D012189:Retrospective Studies; D014700:Verapamil / Q000008:administration & dosage / Q000494:pharmacology*
D002316:Cardiotonic Agents; D014700:Verapamil